FNDC3B

Across TCGA pan-cancer cohorts, FNDC3B mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FNDC3B data layer compared with 30 for mass-spec protein and 12 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FNDC3B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated FNDC3B expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where FNDC3B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	0.677	0.910	<.001	85	view →
PDAC	DFS	Quartile	All	0.303	0.531	.003	20	view →
LSCC	DFS	Median	II,III,IV	0.647	0.899	.008	11	view →
GBM	DFS	Tertile	All	0.225	0.420	.012	9	view →
LUAD	DFS	Tertile	All	0.954	0.843	.007	8	view →
HNSC	OS	Tertile	III,IV	0.572	0.826	.021	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FNDC3B–CCRCC (OS)

Open the CCRCC breakdown →